About 450,000 people a year are infected with multi-drug resistant tuberculosis (MDR-TB), which is resistant to the main firstline drugs isoniazid and rifampin. In addition extensively drug resistant tuberculosis (XDR-TB), which is resistant to isoniazid and rifampin and resistant to any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin) has been reported in 37 countries in all regions of the world since 2006. Moreover human immunodeficiency virus-tuberculosis (HIV-TB) co-infection is also a big challenge besides the XDR-TB. 1 Yet no new anti-TB drug has been introduced since the 1960s. In this context, designing and developing a new anti-TB drug is very important. To date two different biosynthetic pathways have been reported leading to isopentenyl diphosphate, the universal precursor of isoprenoids. The mevalonate pathway 2 is found in animals, whereas the non-mevalonate or methylerythritol phosphate (MEP) pathway is found in many bacteria, some protozoa, and plants (Scheme 1). 3 In the MEP pathway, 1-deoxy-D-xylulose 5-phosphate 5 (DXP)
is made by condensing pyruvate 3 and glyceraldehyde 3-phosphate 4 catalyzed by DXP synthase (Dxs). Subsequently, 1 is synthesized by intramolecular rearrangement and reduction of 5 catalyzed by IspC. Then 1 is coupled with cytidine triphosphate (CTP) using IspD to produce 2. 2 is subsequently phosphorylated by 4-diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate synthase (IspE) to form 4-diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate 6 (CDP-ME2P) and cyclized by IspF to form 2-Cmethyl-D-erythritol 2,4-cyclodiphosphate 7 (ME-CPP). The cyclic diphosphate is transformed into 1-hydroxy-2-methyl-2-E-butenyl 4-diphosphate 8 (HMBPP) by IspG. IspH (LytB) catalyzes the synthesis of isopentenyl diphosphate 9 (IPP) and its isomer dimethylallyl diphosphate 10 (DMAPP).
Since the MEP pathway is not found in mammalian cells, it is considered an attractive target for the development of antimicrobials, antimalarials, and herbicidal agents, 3 a hypothesis that is being explored by an increasing number of researchers. A major difficulty hindering this research is the shortage of pure substrates. In this regard, access to MEP pathway intermediates and their analogues is essential to ongoing biochemical investigations and development of high throughput screens to attempt to identify leads for synthesis of new therapeutics. Recently, we have described assays for mycobacterial Dxs, IspC, and IspD. 4 In order to study mycobacterial IspE, we were in need of compound 2. However, the reported chemical synthesis of 2 is only 50% enantiomerically pure. 5 Whereas when synthesized enzymatically starting with the formation of 5 by condensation of 3 and 4 catalyzed by Dxs, the ultimate yield of 1 is very low. 6 In addition this enzymatic method is time consuming and expensive. Herein, we report a chemoenzymatic method to synthesize 2 in good yield.
To initiate the synthesis of 2 (Scheme 2), we synthesized enantiopure 1. Many procedures are available for the synthesis of 1. However, only one procedure is reported for synthesis of enantiomerically pure 1 from commercially available 1,2-O-isopropylidene-a-D-xylofuranose. 7 Dibenzyl phosphochloridate 8 was synthesized by a modified procedure of chlorinating dibenzyl phosphite 11, in toluene and benzene using N-chlorosuccinamide (NCS Previously, 3-C-alkyl ribofuranoses were obtained by a stereoselective addition reaction with the alkyl group on the b-face of the carbohydrate ring.
9 Accordingly, in the ketone 15, addition of the methyl group occurs from the less hindered b-face, leading to the tertiary alcohol 16 with the desired stereochemistry. The alcohol 16 was protected by using benzyl bromide, after activating the hydroxyl group to yield 90% of benzylated 17.
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Acetonide deprotection was carried out using 90% aq trifluoroacetic acid giving rise to two anomers 18, which underwent a sodium metaperiodate-mediated glycol oxidative cleavage to give the aldehyde 19. The aldehyde was reduced with sodium borohydride forming the MEP precursor, 11 alcohol 20, followed by hydrogenolysis in water/methanol medium, without acid workup leading to enantiomerically pure 1 (Scheme 2). The chemically synthesized 1 was characterized by NMR, MS, and optical rotation, and the data were found to be identical with those previously reported in the literature. 7, 12, 13 Subsequently, chemically synthesized 1 was used as a substrate for the enzymatic synthesis of 2. Recombinant Rv3582c, M. tuberculosis IspD, was prepared as previously described. 4a Briefly, Rv3582c was amplified using PCR primers, and Expand High Fidelity PCR system (Roche Molecular Biochemicals, Indianapolis, Indiana, USA) (Rv3582c-F: CAT ATG AGG GAA GCG GGC GAA GTA G and Rv3582c-R: CTC GAG TCA CCC GCG GAG TAT AGC TTG), containing NdeI and XhoI restriction enzyme sites (underlined), respectively. The PCR products were digested and ligated into the pET28a(+) vector (EMD Biosciences, Inc., San Diego, CA) and the ligation mixtures were used to transform E. Thus, we successfully synthesized enantiomerically pure 1, which could be utilized by mycobacterial IspD to synthesize 2 in satisfactory yields. Radiolabel could be introduced during the methylation or reduction steps if required. Pure 2 can be used to study the kinetic properties of IspE and for high throughput screening to identify IspE inhibitors. Experiments for M. tuberculosis IspE inhibitors are in progress.
